Hyperlipidemia in patients with Type 2 Diabetes Mellitus. Rosuvastatin Atorvastatin Statin LDL Cholesterol Type 2 Diabetes Mellitus Dyslipidemia Hyperlipidemia Randomized Controlled Trial Lipid Profile
Conditions
Interventions
Participants will receive Rosuvastatin 10 mg orally once daily for 12 weeks. Participants will be advised to continue their existing antidiabetic medications unchanged throughout the study period. Adh
Experimental Drug,Active Comparator Drug
Rosuvastatin 10 mg,Atorvastatin 20 mg
Sponsors
Pakistan Emirates Military Hospital, Rawalpindi, Pakistan
Eligibility
Sex/Gender
All
Age
30 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Adults aged 30 to 70 years with a confirmed diagnosis of Type 2 Diabetes Mellitus 2. Primary hyperlipidemia defined as LDL-C greater than 130 mg/dL 3. HbA1c less than 9.0% 4.No prior statin therapy
Exclusion criteria
Exclusion criteria: 1. Secondary causes of hyperlipidemia (e.g., hypothyroidism, nephrotic syndrome) 2. Active liver disease or elevated transaminases more than 3 times the upper limit of normal 3. Pregnant or breastfeeding women 4. History of statin intolerance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LDL Cholesterol Reduction Baseline, 6 weeks, and 12 weeks Mean change in fasting serum LDL-C levels (mg/dL) from baseline to 12 weeks, measured by standardized laboratory lipid panel | — |
Secondary
| Measure | Time frame |
|---|---|
| HDL Cholesterol Change Baseline and 12 weeks Mean change in fasting serum HDL-C levels (mg/dL) from baseline to 12 weeks | — |
Countries
Pakistan
Contacts
Public ContactMuhammad Haseeb Lodhi
National University of Medical Sciences
Outcome results
None listed